Group-Based Trajectory Modeling to Identify Patterns of Antipsychotic-Associated Weight Gain Among Children and Adolescents.

IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Journal of Clinical Psychopharmacology Pub Date : 2024-03-01 Epub Date: 2024-01-23 DOI:10.1097/JCP.0000000000001814
Ning Lyu, Susan Abughosh, Tyler J Varisco, Ying Lin, Paul J Rowan, Hua Chen
{"title":"Group-Based Trajectory Modeling to Identify Patterns of Antipsychotic-Associated Weight Gain Among Children and Adolescents.","authors":"Ning Lyu, Susan Abughosh, Tyler J Varisco, Ying Lin, Paul J Rowan, Hua Chen","doi":"10.1097/JCP.0000000000001814","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose/background: </strong>Antipsychotic-associated weight gain (AAWG) is a common adverse effect of second-generation antipsychotic (SGA) medications among children and adolescents. This study applied group-based trajectory modeling to identify latent trajectories of AAWG among children and adolescents and associated risk factors.</p><p><strong>Procedures: </strong>This was a retrospective analysis of the IQVIA Ambulatory EMR-US database from 2016 to 2021. The cohort consisted of patients aged 6 to 19 years who were SGA naive and received at least 90 days of continuous SGA prescriptions. Group-based trajectory modeling was used to identify latent trajectories of AAWG development during a 24-month period since SGA initiation, and multinomial logistic regression analysis was conducted to examine the risk factors associated with the identified AAWG trajectories.</p><p><strong>Findings/results: </strong>A total of 16,262 patients were included. Group-based trajectory modeling identified the following 4 distinctive AAWG trajectories: persistent severe weight gain (4.2%), persistent moderate weight gain (20.1%), minor weight change (69.6%), and gradual weight loss (6.1%). Compared with the minor weight change group, younger age (12-17 vs 5-11: odds ratio [OR], 0.634; 95% confidence interval [CI], 0.521-0.771), lower baseline body mass index z -score (OR, 0.216; 95% CI, 0.198-0.236), and receiving olanzapine as the initial SGA (olanzapine vs aripiprazole: OR, 1.686; 95% CI, 1.673-1.699) were more likely to follow severe weight gain trajectories. The area under the receiver operating characteristic curves for comparing severe weight gain versus minor weight change groups and moderate weight vs minor weight change groups in the multinomial regression model were 0.91 and 0.8, respectively.</p><p><strong>Implications/conclusions: </strong>A quarter of pediatric SGA recipients experienced persistent weight gain during the SGA treatment. The risk of having persistent AAWG can be predicted using patient characteristics collected before SGA initiation and the initial SGA agent.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JCP.0000000000001814","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose/background: Antipsychotic-associated weight gain (AAWG) is a common adverse effect of second-generation antipsychotic (SGA) medications among children and adolescents. This study applied group-based trajectory modeling to identify latent trajectories of AAWG among children and adolescents and associated risk factors.

Procedures: This was a retrospective analysis of the IQVIA Ambulatory EMR-US database from 2016 to 2021. The cohort consisted of patients aged 6 to 19 years who were SGA naive and received at least 90 days of continuous SGA prescriptions. Group-based trajectory modeling was used to identify latent trajectories of AAWG development during a 24-month period since SGA initiation, and multinomial logistic regression analysis was conducted to examine the risk factors associated with the identified AAWG trajectories.

Findings/results: A total of 16,262 patients were included. Group-based trajectory modeling identified the following 4 distinctive AAWG trajectories: persistent severe weight gain (4.2%), persistent moderate weight gain (20.1%), minor weight change (69.6%), and gradual weight loss (6.1%). Compared with the minor weight change group, younger age (12-17 vs 5-11: odds ratio [OR], 0.634; 95% confidence interval [CI], 0.521-0.771), lower baseline body mass index z -score (OR, 0.216; 95% CI, 0.198-0.236), and receiving olanzapine as the initial SGA (olanzapine vs aripiprazole: OR, 1.686; 95% CI, 1.673-1.699) were more likely to follow severe weight gain trajectories. The area under the receiver operating characteristic curves for comparing severe weight gain versus minor weight change groups and moderate weight vs minor weight change groups in the multinomial regression model were 0.91 and 0.8, respectively.

Implications/conclusions: A quarter of pediatric SGA recipients experienced persistent weight gain during the SGA treatment. The risk of having persistent AAWG can be predicted using patient characteristics collected before SGA initiation and the initial SGA agent.

基于群体的轨迹建模,识别儿童和青少年中与抗精神病药相关的体重增加模式。
目的/背景:抗精神病药物相关体重增加(AAWG)是第二代抗精神病药物(SGA)在儿童和青少年中常见的不良反应。本研究采用基于群体的轨迹建模来确定儿童和青少年的 AAWG 潜在轨迹及相关风险因素:这是一项对 2016 年至 2021 年 IQVIA Ambulatory EMR-US 数据库的回顾性分析。队列包括年龄在 6 至 19 岁之间、未服用 SGA 且连续接受至少 90 天 SGA 处方的患者。研究采用基于群体的轨迹建模来识别自开始使用 SGA 起 24 个月内 AAWG 的潜在发展轨迹,并进行多叉逻辑回归分析来研究与所识别的 AAWG 轨迹相关的风险因素:共纳入 16,262 名患者。基于分组的轨迹建模确定了以下 4 种独特的 AAWG 轨迹:体重持续严重增加(4.2%)、体重持续中度增加(20.1%)、体重轻微变化(69.6%)和体重逐渐减轻(6.1%)。与体重轻微变化组相比,年龄较小(12-17 岁 vs 5-11 岁:几率比[OR],0.634;95% 置信区间[CI],0.521-0.771)、基线体重指数 z 值较低(OR,0.216;95% CI,0.198-0.236)、接受奥氮平作为初始 SGA(奥氮平 vs 阿立哌唑:OR,1.686;95% CI,1.673-1.699)的患者更有可能遵循体重严重增加轨迹。在多项式回归模型中,比较严重体重增加组与轻微体重变化组以及中等体重组与轻微体重变化组的接收者操作特征曲线下面积分别为0.91和0.8:四分之一的小儿 SGA 接受者在接受 SGA 治疗期间体重持续增长。根据开始使用 SGA 前收集的患者特征和初始 SGA 剂型,可以预测持续 AAWG 的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.00
自引率
3.40%
发文量
231
审稿时长
4-8 weeks
期刊介绍: Journal of Clinical Psychopharmacology, a leading publication in psychopharmacology, offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信